Literature DB >> 19180404

[Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].

R Leutgeb1, C Mahler, G Laux, Artenetz Weschnetz, J Szecsenyi.   

Abstract

BACKGROUND AND
OBJECTIVE: The German federal Health Insurance law to strengthen competition between the pharmaceutical companies commits pharmacies to hand out drugs from discount contract drug suppliers of a patient's health insurance company. Thus patients are confronted with constantly changing drug packets. This study aimed at exploring whether patients have been properly informed about the new discount contracts and if they have experienced changes and problems in their long- term medications.
METHODS: Between May and June 2008 male and female patients older than 50 years who had a statutory health insurance and had been diagnosed with coronary heart disease for at least one year answered a standardized questionnaire filled in by doctors' assistants or general practitioners in the doctors' network "Weschnitztal".
RESULTS: Of the 188 patients participated in this study 63,8% were informed about health insurance discount contracts. 31,3% of the patients reported that a positive effect due to the discount contracts was that they were discharged from paying the drug prescription fee, 22,2% mentioned that cost saving for the health insurance could also be positive. 120 patients (63,8%) knew that the names of their long-term drugs could change.101 of the questioned patients (53,7%) identified a change in their long-term drugs, 51,5% felt insecure about the permanent changes. 21,7% experienced adverse e effects due to the new drugs. 19% of the patients had serious problems regarding medication intake.
CONCLUSION: This study demonstrates that the information which patients have on the new health insurance law is not adequate enough. Many of them felt insecure because of the changes of long-term medications. One fifth of the patients reported errors in their drug intake or their confusion about their drugs. There is a high risk that these circumstances may trigger further diseases or complications. The cost savings as intended by the health insurance companies may therefore not be achieved by discount contracts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19180404     DOI: 10.1055/s-0028-1123975

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  5 in total

1.  The effects of rebate contracts on the health care system.

Authors:  Julia Graf
Journal:  Eur J Health Econ       Date:  2013-06-23

2.  Generic substitution, financial interests, and imperfect agency.

Authors:  Maurus Rischatsch; Maria Trottmann; Peter Zweifel
Journal:  Int J Health Care Finance Econ       Date:  2013-03-14

3.  Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists.

Authors:  Gunter Laux; Sarah Berger; Joachim Szecsenyi; Petra Kaufmann-Kolle; Rüdiger Leutgeb
Journal:  BMC Fam Pract       Date:  2016-10-19       Impact factor: 2.497

4.  [Prescribing behavior of Bavarian general practitioners at the inpatient-outpatient interface within the context of the Bavarian active substance agreement-qualitative results of the WirtMed Study].

Authors:  Nikoletta Zeschick; Julia Gollnick; Julia Muth; Franziska Hörbrand; Peter Killian; Wolfgang Krombholz; Norbert Donner-Banzhoff; Thomas Kühlein; Maria Sebastião
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-07-15       Impact factor: 1.595

5.  Factors associated with medication information in diabetes care: differences in perceptions between patients and health care professionals.

Authors:  Gerda Längst; Hanna Marita Seidling; Marion Stützle; Dominik Ose; Ines Baudendistel; Joachim Szecsenyi; Michel Wensing; Cornelia Mahler
Journal:  Patient Prefer Adherence       Date:  2015-10-14       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.